140 related articles for article (PubMed ID: 28045782)
1. Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.
de Krou S; Rosing H; Nuijen B; Schellens JH; Beijnen JH
Ther Drug Monit; 2017 Apr; 39(2):132-137. PubMed ID: 28045782
[TBL] [Abstract][Full Text] [Related]
2. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
[TBL] [Abstract][Full Text] [Related]
3. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
Antunes MV; Raymundo S; de Oliveira V; Staudt DE; Gössling G; Peteffi GP; Biazús JV; Cavalheiro JA; Tre-Hardy M; Capron A; Haufroid V; Wallemacq P; Schwartsmann G; Linden R
Talanta; 2015 Jan; 132():775-84. PubMed ID: 25476377
[TBL] [Abstract][Full Text] [Related]
4. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Arellano C; Allal B; Goubaa A; Roché H; Chatelut E
J Pharm Biomed Anal; 2014 Nov; 100():254-261. PubMed ID: 25173109
[TBL] [Abstract][Full Text] [Related]
5. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
[TBL] [Abstract][Full Text] [Related]
6. Development of a high-performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen and 4-hydroxytamoxifen in plasma from breast cancer patients.
Rangel-Méndez JA; Graniel-Sabido MJ; Sánchez-Cruz JF; Moo-Puc R
Biomed Chromatogr; 2019 Apr; 33(4):e4462. PubMed ID: 30536934
[TBL] [Abstract][Full Text] [Related]
7. Determination of tamoxifen and endoxifen in dried blood spots using LC-MS/MS and the effect of coated DBS cards on recovery and matrix effects.
Jager NG; Rosing H; Schellens JH; Beijnen JH
Bioanalysis; 2014; 6(22):2999-3009. PubMed ID: 25496254
[TBL] [Abstract][Full Text] [Related]
8. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer.
Sanchez-Spitman AB; Moes DAR; Swen JJ; Dezentjé VO; Lambrechts D; Neven P; Gelderblom H; Guchelaar HJ
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1141-1152. PubMed ID: 32468081
[TBL] [Abstract][Full Text] [Related]
9. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study.
Sanchez-Spitman A; Dezentjé V; Swen J; Moes DJAR; Böhringer S; Batman E; van Druten E; Smorenburg C; van Bochove A; Zeillemaker A; Jongen L; Los M; Neven P; Gelderblom H; Guchelaar HJ
J Clin Oncol; 2019 Mar; 37(8):636-646. PubMed ID: 30676859
[TBL] [Abstract][Full Text] [Related]
11. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
12. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
[TBL] [Abstract][Full Text] [Related]
14. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.
Jager NG; Rosing H; Schellens JH; Beijnen JH; Linn SC
Breast Cancer Res Treat; 2014 Jul; 146(1):137-44. PubMed ID: 24859000
[TBL] [Abstract][Full Text] [Related]
15. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.
Nardin JM; Schroth W; Almeida TA; Mürdter T; Picolotto S; Vendramini ECL; Hoppe R; Kogin JP; Miqueleto D; de Moraes SDR; Schwab M; Pecoits-Filho RF; Brauch H; Casali-da-Rocha JC
Clin Transl Sci; 2020 Mar; 13(2):284-292. PubMed ID: 31573754
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
17. Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients.
Maggadani BP; Harmita ; Haryono SJ; Rinaldi MR; Harahap Y
Drug Des Devel Ther; 2021; 15():2417-2430. PubMed ID: 34113081
[TBL] [Abstract][Full Text] [Related]
18. Reductive amination-assisted quantitation of tamoxifen and its metabolites by liquid phase chromatography tandem mass spectrometry.
Liang SS; Wang TN; Chiu CC; Kuo PL; Huang MF; Liu MC; Tsai EM
J Chromatogr A; 2016 Feb; 1434():64-9. PubMed ID: 26814364
[TBL] [Abstract][Full Text] [Related]
19. Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines.
Aranda EO; Esteve-Romero J; Rambla-Alegre M; Peris-Vicente J; Bose D
Talanta; 2011 Apr; 84(2):314-8. PubMed ID: 21376950
[TBL] [Abstract][Full Text] [Related]
20. Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.
Antunes MV; Rosa DD; Viana Tdos S; Andreolla H; Fontanive TO; Linden R
J Pharm Biomed Anal; 2013 Mar; 76():13-20. PubMed ID: 23291438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]